Thermo Fisher Scientific Inc. (TMO) - Stock Analysis

Last updated: Jul 25, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Q3 2025 earnings beat with raised full-year guidance, strategic AI collaborations, share repurchase program, and positive technical momentum with 7.4% price gain support Thermo Fisher Scientific as an actionable hot idea for moderate near-term growth.

Loading chart data...

Idea window: 11/17/2025 – 11/24/2025Sector: Healthcare

AI Analyst Overview

Last Price
$576.41
Market Cap
$168.20B
1D Return
+3.02%
YTD Return
-0.33%

Loading chart data...

Valuation Metrics

P/E
24.6
P/B
3.2
P/S
3.7
EV/EBITDA
18.9
Div Yield
0.39%

Price Behavior

7.0

Key Price Behavior Insights: • Higher-high trend • Breakout support • Volatility spike Support Level: $523-$526 Resistance Level: low $570s Over the last month, TMO has stayed in a constructive short-term uptrend with higher highs/lows, support now near $523-$526, and while momentum is positive, the quick run into the low $570s suggests it may need consolidation before extending further.

Bullish
Consolidation

Sentiment & News

8.0

Key News Insights: • Q2 Beat • Raised Outlook • Demand Recovery Thermo Fisher shifted from cautious sentiment to a more positive setup after beating Q2 expectations, raising full-year guidance, and signaling improving end-market demand despite earlier NIH/China and integration concerns.

earnings
guidance
AI

AI Summary

7.0
Positive

TMO's latest quarter shifts the thesis from a slow-recovery compounder to a real earnings re-acceleration story, but with the stock already rerating, the investment case now hinges on proving that improved demand and operating leverage are durable enough to justify the premium valuation rather than a one-quarter rebound.

EarningsReacceleration
ValuationRisk
QualityCompounder
AI summary updated 3 days ago

Description

Thermo Fisher Scientific is a global provider of instruments, reagents, consumables and services for life sciences research, clinical diagnostics, and biopharmaceutical production across North America, Europe, Asia-Pacific and other markets. The company operates through four reporting segments—life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services—selling to pharmaceutical, biotechnology, clinical, academic, government and industrial customers via direct sales, e-commerce and distributors. Founded in 1956, Thermo Fisher is headquartered in Waltham, Massachusetts.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Nov 17Nov 24TMOThermo Fisher Scientific Inc.
Q3 2025 earnings beat with raised full-year guidance, strategic AI collaborations, share repurchase program, and positive technical momentum with 7.4% price gain support Thermo Fisher Scientific as an actionable hot idea for moderate near-term growth.
Closed+3.3%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.